e-Drug3D

2070

ADAGRASIB

INN
ADAGRASIB

cas 2326521-71-3

CLASS

ANTINEOPLASTIC
COVALENT INHIBITOR OF THE RAS GTPASE FAMILY KRAS G12C MUTANT
TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

ROUTE (list)

ORAL

ATC code

L01XX77

PK parameters

Tmax 6 HOUR
VD 942 LITER
Cl 37 LITER / HOUR
PPB 98 PERCENT
t1/2 23 HOUR

Solubility

LESS THAN 0.010 MILLIGRAM PER MILLITER AT PH 7.4

Target

TARGET KRAS G12C

DrugCentral

GTPase KRas UNIPROT P01116

Download SDF file

2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)- (ACI)

Formula:
C32H35ClFN7O2

Calculated chemical properties:

MW 604.12
NB_atoms 43
XLogP 4.73
PSA 70.008
NB_HD 0
NB_HA 9
fsp3 0.44
Lipinski(0=no;1=yes) 0

FDA
NDA 216340 (pdf not found) INN (ADAGRASIB) KRAZATI (BRISTOL) APPROVAL= AP YEAR= 2022 NEWMOLECULARENTITY